## 504161320 01/03/2017 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4207996

SUBMISSION TYPE:		NEW ASSIGNM	NEW ASSIGNMENT				
NATURE OF CONVEYANCE:		SECURITY INT	SECURITY INTEREST				
CONVEYING PARTY DA	ATA						
		Name	Name		ecution Date		
NEKTAR THERAPEUTIC	CS				0/2016		
RECEIVING PARTY DA	1						
Name:	TC LENDING, LLC, AS COLLATERAL AGENT						
Street Address:	301 COMMERCE STREET						
Internal Address:	SUITE 3300						
City:	FORTH WORTH						
State/Country:	TEXAS						
Postal Code:	76102						
PROPERTY NUMBERS	Total: 9			1			
Property Type		Number					
Application Number:		5301681					
Application Number:		5294148					
Application Number:		296414					
Application Number:		15331461					
Application Number: 1		5341470					
Application Number:		52420442					
		424798		1			
_ · ·		359344	59344				
		360405					
Fax Number:	· · ·	15)339-5323	livat, if that is use		ll ha aant		
Correspondence will be using a fax number, if p					II DE SENT		
Email:	using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail. Email:atran@nektar.com						
Correspondent Name: NEK		EKTAR THERAPEU	TAR THERAPEUTICS				
Address Line 1: 455		5 MISSION BAY BO	MISSION BAY BOULEVARD SOUTH				
		JITE 100					
Address Line 4:	S	AN FRANCISCO, C	ALIFORNIA 94158	3			
NAME OF SUBMITTER:		SUSAN T. EVA	NS				

SIGNATURE:	/Susan T. Evans/				
DATE SIGNED:	01/03/2017				
Total Attachments: 4 source=US Security Grant December 2016 Fully Executed#page1.tif source=US Security Grant December 2016 Fully Executed#page2.tif					
source=US Security Grant December 2016 Fully Executed#page3.tif source=US Security Grant December 2016 Fully Executed#page4.tif					

#### GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS

FOR GOOD AND VALUABLE CONSIDERATION, receipt and sufficiency of which are hereby acknowledged, Nektar Therapeutics, a Delaware corporation (the "<u>Grantor</u>") with principal offices at 455 Mission Bay Blvd South, Suite 100, San Francisco, CA 94158, hereby grants to TC Lending, LLC, as Collateral Agent, with principal offices at 301 Commerce Street, Suite 3300, Fort Worth, TX 76102, (the "<u>Grantee</u>"), a continuing security interest in (i) all of the Grantor's rights, title and interest in, to and under the United States patents (the "<u>Patents</u>") set forth on Schedule A attached hereto, in each case together with (ii) all proceeds (as such term is defined in the Uniform Commercial Code of the State of New York as in effect from time to time) and products of the Patents, and (iii) all causes of action arising prior to or after the date hereof for infringement of any of the Patents or unfair competition regarding the same.

THIS GRANT is made to secure the satisfactory performance and payment of all the Obligations of the Grantor, as such term is defined in the Pledge and Security Agreement among the Grantor, the other Grantors from time to time party thereto and the Grantee, dated as of October 5, 2015 (as amended, modified, restated and/or supplemented from time to time, the "<u>Security Agreement</u>"). Upon the occurrence of the Termination Date (as defined in the Security Agreement), the Grantee shall execute, acknowledge, and deliver to the Grantor an instrument in writing releasing the security interest in the Patents acquired under this Grant.

THIS GRANT has been granted in conjunction with the security interest granted to the Grantee under the Security Agreement. The rights and remedies of the Grantee with respect to the security interest granted herein are as set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

IN WITNESS WHEREOF, the undersigned have executed this Grant as of the  $20^{n}$  day of December, 2016.

### NEKTAR THERAPEUTICS, Grantor

By:

Mal U. Milson Name: Mark A. Wilson 

Title: Vice President and General Counsel

IN WITNESS WHEREOF, the undersigned have executed this Grant as of the  $\frac{21^{34}}{21^{34}}$  day of <u>December</u>, 2016.

TC LENDING, LLC, as Collateral Agent and Grantee

By:

Name: Michael Fishman

 Name:
 Michael Fishmän

 Title:
 Co-Chief Executive Officer

### PATENT REEL: 040828 FRAME: 0886

# SCHEDULE A

•

÷

•

٤

Title	Serial No.	Filing Date
CONJUGATES OF AN IL-15 MOIETY AND A POLYMER	15/301,681	10/03/2016
N-MALEIMIDYL POLYMER DERIVATIVES	15/294,148	10/14/2016
MULTI-ARM POLYMERIC ALKANOATE CONJUGATES	15/296,414	10/18/2016
COMPOSITIONS OF PARTICULATE COFORMULATION	15/331,461	10/21/2016
OLIGOMER-OPIOID AGONIST CONJUGATES	15/341,470	11/02/2016
IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD	62/420,442	11/10/2016
LONG-ACTING IL-2 RECEPTOR AGONIST	62/424,798	11/21/2016
METHOD FOR PREPARING FUNCTIONALIZED POLYMERS FROM POLYMERIC ALCOHOLS	15/359,344	11/22/2016
SYSTEMS AND METHODS FOR DRIVING NEBULIZERS	15/360,405	11/23/2016

•

•